Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109384 | PMC |
| http://dx.doi.org/10.1159/000504893 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent Gynecomastia due to Short-term Low-dose Finasteride for Androgenetic Alopecia.
JCEM Case Rep
May 2024
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
We report a case of persistent gynecomastia in a healthy 20-year-old man after 1 month of low-dose finasteride. Finasteride was discontinued after 2 months, and gynecomastia was unchanged 5 months after drug withdrawal. The gynecomastia regressed but did not resolve after 6 months of treatment with raloxifene, a selective estrogen receptor modulator.
View Article and Find Full Text PDFMedications Mostly Associated With Ejaculatory Disorders: Assessment of the Eudra-Vigilance and Food and Drug Administration Pharmacovigilance Databases Entries.
Urology
March 2024
'Sapienza' University of Rome, Department of Urology, Rome, Italy. Electronic address:
Objective: To identify which medications are mostly associated with ejaculatory disorders through a disproportionality analysis.
Methods: The Food and Drug Administration Adverse Event Reporting System (FDA-FAERS) and the Eudra-Vigilance (EV) database were queried to identify medications more commonly associated to ejaculatory disorders from September 10, 2012 to June 1, 2023. Proportional Reported Ratios (PRRs) were computed for all the selected drugs.
Beliefs and counseling practices among dermatologists regarding sexual and other adverse effects of finasteride.
Int J Impot Res
August 2023
Harvard Medical School, Boston, MA, USA.
Finasteride may cause low libido and erectile dysfunction and the product label of finasteride also includes post-marketing reactions of sexual dysfunction that continued after discontinuation of treatment, as well as male infertility and depression. The aim of this study was to evaluate the beliefs and counseling practices among dermatologists regarding adverse effects of finasteride. Anonymous paper surveys were personally distributed to 122 attendees at two annual major dermatology meetings.
View Article and Find Full Text PDFMedications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database.
Sex Med
October 2022
Division of Urology, Maimonides Medical Center, New York, NY, USA.
Background: Erectile dysfunction (ED) is an adverse effect of many medications.
Aim: We used a national pharmacovigilance database to assess which medications had the highest reported frequency of ED.
Methods: The Food and Drug Administration Adverse Event Reporting System (FAERS) was queried to identify medications with the highest frequency of ED adverse event reports from 2010 to 2020.
Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
JAMA Netw Open
November 2021
San Francisco Veterans Affairs Medical Center, San Francisco, California.
Importance: Benign prostatic hyperplasia (BPH) in older men can cause lower urinary tract symptoms (LUTS), which are increasingly managed with medications. Frailty may contribute to both symptom progression and serious adverse events (SAEs), shifting the balance of benefits and harms of drug therapy.
Objective: To assess the association between a deficit accumulation frailty index and clinical BPH progression or SAE.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!